Hepatitis B after transplantation: Competition between the recipient virus and the donor virus
David Mutimer – 9 September 2010
Utility of uncalibrated femoral stroke volume variation as a predictor of fluid responsiveness during the anhepatic phase of liver transplantation
Young Hee Shin, Justin Sangwook Ko, Mi Sook Gwak, Gaab Soo Kim, Jong Hwan Lee, Suk‐Koo Lee – 9 September 2010 – We evaluated the value of the stroke volume variation (SVV) calculated with the Vigileo monitor, which recently has been increasingly advocated for fluid management, as a predictor of fluid responsiveness during the anhepatic phase of liver transplantation (LT). We also compared SVV to the central venous pressure (CVP) and pulmonary arterial occlusion pressure (PAOP) in patients. Thirty‐three adult recipients scheduled for elective living donor LT were enrolled in this study.
Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection
Martin Lagging, Åsa Alsiö, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Kristoffer Hellstrand, Gunnar Norkrans – 7 September 2010
The next step for taribavirin
Paul Y. Kwo, Rakesh Vinayek – 7 September 2010
Observed and calculated interleukin‐28B genotype frequencies in hepatitis C virus infection
Magnus Lindh, Martin Lagging, Gunnar Norkrans, Kristoffer Hellstrand – 7 September 2010
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells
Mei‐Chuan Chen, Chun‐Han Chen, Hsiao‐Ching Chuang, Samuel K. Kulp, Che‐Ming Teng, Ching‐Shih Chen – 7 September 2010 – Histone deacetylase (HDAC) inhibitors exhibit a unique ability to degrade topoisomerase (topo)IIα in hepatocellular carcinoma (HCC) cells, which contrasts with the effect of topoII‐targeted drugs on topoIIβ degradation. This selective degradation might foster novel strategies for HCC treatment in light of the correlation of topoIIα overexpression with the aggressive tumor phenotype and chemoresistance.
Small‐duct sclerosing cholangitis associated with Schistosoma mansoni
Catherine H. McCrann, James L. Boyer – 7 September 2010
Treatment of acute hepatitis C in human immunodeficiency virus–infected patients: The HEPAIG study
Lionel Piroth, Christine Larsen, Christine Binquet, Laurent Alric, Isabelle Auperin, Marie‐Laure Chaix, Stéphanie Dominguez, Xavier Duval, Anne Gervais, Jade Ghosn, Elisabeth Delarocque‐Astagneau, Stanislas Pol – 7 September 2010 – Acute hepatitis C continues to be a concern in men who have sex with men (MSM), and its optimal management has yet to be established.
Reply:
Carlos M. Rodriguez‐Ortigosa, Fernando Corrales, Juan F. Medina, Jesús Prieto – 7 September 2010
Activation of serotonin receptor‐2B rescues small‐for‐size liver graft failure in mice
Yinghua Tian, Rolf Graf, Ashraf Mohammad El‐Badry, Mickaël Lesurtel, Katarzyna Furrer, Wolfgang Moritz, Pierre‐Alain Clavien – 7 September 2010 – The implantation of grafts below 30% of the normal liver volume is associated with a high risk of failure known as small‐for‐size (SFS) syndrome. Strategies to rescue small grafts may have a dramatic impact on organ shortage. Serotonin is a potent growth factor for the liver. The goal of this study was to determine whether enhanced serotonin signaling could prevent the deleterious effects of SFS syndrome.